Management Of Upper Tract Urothelial Carcinoma

Introduction

Urothelial carcinoma is the fourth most common type of solid cancer. The majority (90 to 95 percent) occur in the lower urinary tract, which comprises the urethra and bladder. The remaining stones are found in the upper urinary tract and occur in the renal pelvis, renal calyces, and ureter. Upper tract urothelial carcinomas (UTUC) appear like lower tract urothelial carcinomas when examined under the microscope. Interestingly, even though they look almost similar under the microscope, UTUC and bladder cancer have different genetic and epigenetic makeups. That is why doctors sometimes call them 'dissimilar twins’. UTUCs are rare, accounting for five to ten percent of urothelial carcinomas (UCs). UTUC has a distinct natural history from UCB (urinary carcinoma of the bladder), and at diagnosis, UTUC has a greater incidence of local spread. Hereditary nonpolyposis colorectal cancer (explain) has been associated with a family history of UTUCs, and these individuals can be tested during screening.

Risk Factors of Upper Tract Urothelial Carcinoma

Several environmental factors can affect your risk of developing a UTUC. For example, smoking can significantly increase your chances up to 2.5 to 7 times higher! In the past, a type of UTUC or amino tumors was linked to certain jobs where people were exposed to cancer-causing chemicals called aromatic amines, like benzidine and β-naphthalene.

It takes approximately seven years to develop UTUC following exposure. In other instances, it may take 20 years after exposure ceases. Research indicates that aristolochic acid in the Aristolochia fangchi and clematis plants causes cancer.

The chemical d-aristolactam, derived from aristolochic acid, is associated with a particular p53 gene change at position 139. The mutation occurs in individuals with UTUC who develop kidney disease from Chinese herbs or Balkan endemic nephropathy. While Balkan endemic nephropathy is declining, aristolochic acid remains responsible for this illness. Think of aristolochic acid like a hidden danger in some plants, where long-term exposure can increase your risk of developing UTUC.

Underlying Molecular Pathways for UTUC

We are still learning a lot about the specificity of UTUC at the molecular level, and researchers often compare it to bladder urothelial carcinoma. Interestingly, even though UTUC and bladder cancer appear almost similar under the microscope, they have many differences in how they affect people and what occurs at a genetic level, suggesting various underlying causes.

Understanding these molecular pathways is crucial because it offers the possibility of therapeutic targets. Sfakianos et al.and colleagues recently developed a unique next-generation sequencing technique to discover somatic mutations and copy number variations in 300 cancer-associated genes in tumor and germline DNA from UTUC and bladder urothelial carcinoma patients.

Although the mutant genes were comparable, the frequency of variations in certain repeatedly mutated genes, such as FGFR3, HRAS, TP53, and RB1, differed. Compared to high-grade bladder urothelial carcinoma, high-grade UTUC had more FGFR3 and HRAS mutations and fewer TP53 and RB1.

How Is Upper Tract Urothelial Carcinoma Diagnosed?

To diagnose and stage UTUC, doctors often use various imaging techniques, such as ureteroscopy (a tiny camera), urine cytology (urine tests), and special CT scans called CT urography, to get a clear picture of the tumors. Staging mainly depends on the depth of tumor invasion, lymph node presence, and metastasis; staging is established.

1. Imaging Tests: CT urography is the gold standard for diagnosing upper tract urothelial carcinoma, yielding detailed images of the kidneys and ureters. MRI (Magnetic Resonance Imaging) or ultrasound can sometimes be recommended.

2. Urine Cytology and Biomarkers: Urine is checked for cancer cells, and markers such as NMP22 or UroVysion might be used to detect UTUC.

3. Ureteroscopy and Biopsy: A flexible, thin scope is passed into the urinary tract to identify tumors and take a tissue biopsy to confirm.

4. Retrograde Pyelography: This medical X-ray test applies contrast dye to outline deviations in the upper urinary tract.

How UTUC might progress depends on several factors, such as how far the tumor has spread (stage), how abnormal the cells look (grade), and whether it has spread to the lymph nodes. The good news is that identifying it early can greatly improve the chances of survival. The Staging and grading of UTUC are important to establish the disease severity and extent., Staging determines the extent of tumor spread, and grading determines cell abnormalities to anticipate aggressiveness.

How Is Upper Tract Urothelial Carcinoma Managed?

Management of UTUCis as follows:

1. Kidney-Sparing Surgery: Kidney-sparing surgery (KSS) is an excellent choice for low-risk UTUC since it spares major surgery, maintains the kidney in good function, and has comparable survival rates to total kidney removal. This approach should thus be considered in all low-risk patients, regardless of the condition of the other kidney. Moreover, it might be explored in individuals with severe renal insufficiency or a single kidney.

2. Ureteroscopy: Endoscopic ablation can be explored in individuals with clinically low-risk malignancy in the following cases:

• Laser generators and pliers are provided for biopsies.

• If a flexible instead of a rigid ureteroscope is accessible, use it.

• The patient is warned of needing an early, closer, and stricter observation.

• Complete resection of the tumor or elimination is possible.

• Yet, there is a danger of understating and undergrading with endoscopic treatment.

1. Percutaneous Access: Percutaneous intervention should be performed for low-risk UTUC in the renal pelvis. This procedure may treat low-risk tumors in the lower calyceal system that are not accessible or hard to manage using flexible ureteroscopy. Nevertheless, this procedure is being utilized less frequently due to the advent of better endoscopic equipment, like the distal-tip deflection of modern ureteroscopes. With a percutaneous approach, the possibility of tumor seeding exists.

2. Segmental Ureteral Resection: By sparing the ipsilateral (same side) kidney, segmental ureteral resection with broad margins gives appropriate histopathological samples for staging and grading of cancer. Lymphadenectomy (excision of the regional lymph nodes) can also be done during segmental ureteral resection. Total distal ureterectomy with neo-cystostomy (surgical bladder implantation) is appropriate for low-risk distal ureter tumors, which cannot be excised fully endoscopically, and high-risk tumors when KSS for preserving renal function. The iliac and lumbar ureters fail faster than the distal pelvic ureter. Partial pyelotomy or partial nephrectomy is very rare. Open excision of tumors of the renal pelvis or calyces has been practically stopped.

3. Adjuvant Topical Agents: During kidney-sparing therapy or for the treatment of CIS (carcinoma in situ), antegrade (upwards) administration of bacillus Calmette-Guérin (BCG) vaccine or Mitomycin C in the upper urinary tract by percutaneous nephrostomy using a three-valve system open at 20 cm (after total tumor removal) is possible. Retrograde (downward) instillation through a ureteric stent is also employed. However, it is risky because of the possibility of a ureteral blockage and subsequent pyelovenous inflow following instillation or perfusion. Reflux from a double-J stent has been employed. However, it is not recommended because it frequently does not reach the renal pelvis.

4. Radical Nephroureterectomy (RNU): For high-risk UTUC, the usual surgical approach is called a radical nephroureterectomy, or RNU. It involves removing the complete kidney and the ureter, and a small area of the bladder, irrespective of where the tumor is located. RNU must adhere to oncological principles, such as avoiding tumor seeding by limiting entrance into the urinary system while removing. The distal ureter and its opening are excised since there is a high probability of tumor recurrence in this location. It is difficult to visualize or access the proximal ureter once it has been removed. After RNU, the distal ureter and bladder cuff should be removed. Various procedures, such as plucking, stripping, transurethral resection of the intramural ureter, and intussusception, have been suggested to aid distal ureter excision. All of these procedures are equal to bladder cuff excision except for ureteral stripping.

5. Laparoscopic RNU: Several examples of retroperitoneal metastatic spread and metastases through the trocar system following the management of massive tumors in a pneumoperitoneum environment have been described. Various measures can be taken to reduce the risk of tumor spillage:

• Do not penetrate the urinary tract.

• Avoid putting equipment in direct contact with the tumor.

• Laparoscopic RNU must be performed within a closed system. To avoid tumor morcellation, utilize an endo bag for tumor resection.

• The kidney and ureter must be extracted together with the bladder cuff.

• Until proven otherwise, invasive or huge tumors are contraindicated for laparoscopic RNU.

Different Treatment Options for UTUC

UTUC treatment options depend on the patient's tumor stage, grade, and medical condition.

Ureteral cancer treatment can consist of:

1. Surgery: Kidney and ureter removal via nephroureterectomy is the typical operation for high-grade cases, with kidney-preserving surgeries such as endoscopic ablation being tried for low-grade tumors.

2. Chemotherapy: Neoadjuvant or adjuvant chemotherapy applies systemic chemotherapy to prevent recurrence, most notably in more advanced cases.

3. Immunotherapy: In metastatic UTUC, immune checkpoint inhibitors can improve the immune system to attack cancer cells.

4. Targeted Therapy: Targeted drugs may stop cancer from growing in patients with specific genetic mutations in UTUC.

5. Minimally Invasive Techniques: Select patients are considered for laser ablation or segmental ureterectomy to maintain kidney function.

Conclusion

A complete understanding of the epidemiological variables and molecular mechanisms is necessary for successful UTUC management. For low-risk conditions, kidney-sparing surgery is used, and for high-risk diseases, a radical nephroureterectomy is performed. With increased scientific evidence and research in urothelial carcinoma, perioperative immunotherapy and chemotherapy may be explored.

Key Takeaway/A Note from Icliniq

Upper tract urothelial carcinoma is an aggressive, rare malignancy of the renal pelvis and ureter, frequently necessitating multifaceted treatment plans. It is a highly recurrent and progressive malignancy that can compromise kidney function. Imaging, urine cytology, and ureteroscopy with biopsy are used to diagnose and stage UTUC. UTUC treatment involves surgery, chemotherapy, immunotherapy, and minimally invasive intervention for carefully selected cases. Early diagnosis, modern diagnostic methods, and individualized treatment strategies all enhance patient survival and overall prognosis. If you know anyone in your family, do not hesitate to consult with experts at iCliniq.com.